<DOC>
	<DOCNO>NCT02152332</DOCNO>
	<brief_summary>The purpose study evaluate effect JNJ-54861911 QT/QTc interval healthy participant , administer therapeutic ( 50 milligram [ mg ] once-daily ) supratherapeutic ( 150 mg once-daily ) dose 7 day .</brief_summary>
	<brief_title>A Study Evaluate Effects JNJ-54861911 Electrocardiogram Intervals Healthy Particiants</brief_title>
	<detailed_description>This Phase 1 , double blind ( medical research study neither researcher participant know treatment participant receive ) , randomize ( study drug assign chance ) , placebo positive-controlled , multiple-dose , 4-way crossover ( method use switch participant one study group another ) study . The study consist 3 part : Screening period ( Days -21 -2 ) , Double-blind treatment period End-of-study/early withdrawal assessment period ( 9 13 day last dose ) . Treatment period comprise 4 treatment regimen consist baseline assessment treatment regime ( Days -1 9 ) . The participant randomly assign 1 4 treatment sequence group ( ADBC , BACD , CBDA , DCAB ) base computer-generated randomization schedule receive follow 4 treatment order specify randomization : Treatment A ( JNJ-54861911 , 50 milligram ( mg ) daily 7 day plus moxifloxacin-matched placebo Day 7 ) ; Treatment B ( JNJ-54861911 , 150 mg daily 7 day plus moxifloxacin-matched placebo Day 7 ) ; Treatment C ( JNJ-54861911-matched placebo daily 7 day plus moxifloxacin-matched placebo Day 7 ) ; Treatment D ( JNJ-54861911-matched placebo daily 7 day plus moxifloxacin 400 mg Day 7 ) . Each treatment period separate washout period least 6 - 10 day . Total duration study participant 93 day . Change Baseline QT/QTc interval Day 7 evaluate primary end point . Participant 's safety monitor throughout study .</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Signed informed consent document indicate understand purpose procedure require study , include require pharmacogenomics component ( specifies test gene predispose long short QT related cardiac syndrome ) , willing participate study If woman , must either ) Not childbearing potential : postmenopausal ( great [ &gt; ] 45 year age amenorrhea least 2 year , age amenorrhea least 6 month serum follicle stimulate hormone [ FSH ] &gt; 40 international unit per milliliter [ IU/mL ] ) surgically sterile ; b ) Of childbearing potential practicing effective method birth control If man , sexually active woman childbearing potential vasectomy , must agree use adequate contraception method deem appropriate investigator An average triplicate 12lead electrocardiogram ( ECG ) recording , complete within 4 minute total , consistent normal cardiac conduction function , include : ) normal sinus rhythm heart rate 45 100 beat per minute ( inclusive ) ; b ) QTcF interval 350 450 millisecond , inclusive ; c ) QRS interval le ( &lt; ) 110 millisecond ; ) PR interval &lt; 200 millisecond ; e ) PR interval &lt; 200 millisecond ; f ) ECG morphology consistent healthy cardiac conduction function Blood pressure ( participant remain supine 5 minute ) 90 140 milimeters mercury ( mmHg ) systolic , inclusive , high 90 mmHg diastolic History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , gastrointestinal disease , illness investigator considers exclude parrticipants could interfere interpretation study result History additional risk factor torsade de pointes presence family history Short QT Syndrome , Long QT Syndrome , abnormal bleed blood clotting , sudden unexplained death young age ( less than/equal 40 year ) , drown sudden infant death syndrome first degree relative ( , biological parent , sibling , child ) Use prescription medication ( exception hormonal contraceptive hormonal replacement therapy ) within 14 day Day 1 Period 1 ; use nonprescription medication ( include vitamin herbal supplement St. John 's Wort ) except acetaminophen , within 30 day Day 1 Period 1 ; acetaminophen within 3 day study drug administration treatment period Clinically significant abnormal value hematology , clinical chemistry ( include hypo hyperkalemia , magnesemia , calcemia ) urinalysis Screening admission study center Period 1 deem appropriate Investigator Clinically significant abnormal physical examination , vital sign 12lead ECG Screening admission study center Period 1 deem appropriate Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>JNJ-54861912</keyword>
	<keyword>RSC-385896</keyword>
	<keyword>MTS-0385896A</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Moxifloxacin</keyword>
	<keyword>Placebo</keyword>
	<keyword>Healthy</keyword>
</DOC>